Table 1 Baseline characteristics according to statin therapy.
From: Benefits of statin therapy within a year after kidney transplantation
Statin (n = 414) | Control (n = 300) | p-value | |
|---|---|---|---|
Recipients | |||
Age, years | 47.2 ± 10.7 | 43.4 ± 13.0 | < 0.001 |
Male, n (%) | 254 (61.4) | 204 (68.0) | 0.080 |
Dialysis vintage, months | 23.0 ± 37.7 | 26.1 ± 44.1 | 0.341 |
Donor-specific antibodies, n (%) | 29 (7.0) | 19 (6.3) | 0.840 |
ABO incompatible KT, n (%) | 76 (18.4) | 64 (21.3) | 0.372 |
Donors | |||
Deceased donor, n (%) | 68 (16.4) | 53 (17.7) | 0.737 |
Donor age, years | 43.9 ± 11.7 | 44.6 ± 12.2 | 0.407 |
Male donor, n (%) | 206 (49.8) | 137 (45.7) | 0.315 |
eGFR, mL/min/1.73m2 | 90.7 ± 27.0 | 91.1 ± 28.4 | 0.848 |
Hypertension, n (%) | 50 (12.1) | 40 (13.3) | 0.700 |
Diabetes mellitus, n (%) | 16 (3.9) | 6 (2.0) | 0.229 |
Systolic blood pressure, mmHg | 122.2 ± 15.7 | 119.9 ± 18.6 | 0.077 |
Body mass index, kg/m2 | 23.8 ± 3.1 | 23.8 ± 3.0 | 0.981 |
Recipient cardiovascular risk factors | |||
Body mass index, kg/m2 | 23.3 ± 3.6 | 22.1 ± 3.3 | < 0.001 |
Hypertension, n (%) | 385 (93.0) | 275 (91.7) | 0.604 |
Waist-hip ratio | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.686 |
Diabetes mellitus, n (%) | 118 (28.5) | 64 (21.3) | 0.037 |
MACE prior to KT, n (%) | 43 (10.4) | 20 (6.7) | 0.113 |
Statin use prior to KT, n (%) | 173 (41.8) | 50 (16.7) | < 0.001 |
LDL-cholesterol, mg/dL | 88.6 ± 33.1 | 76.5 ± 28.1 | < 0.001 |
HDL-cholesterol, mg/dL | 44.9 ± 15.6 | 46.0 ± 17.7 | 0.383 |
Total cholesterol, mg/dL | 163.0 ± 43.4 | 144.4 ± 38.6 | < 0.001 |
Recipient smoking, n (%) | 0.743 | ||
Current | 26 (6.3) | 21 (7.0) | |
Former | 170 (41.1%) | 115 (38.3) | |
Systolic blood pressure, mmHg | 138.1 ± 18.5 | 135.7 ± 19.1 | 0.081 |
